摘要Background and aim:Whereas Yttrium-90 selective internal radiation therapy(Y-90 SIRT)was shown to improve local tumor control in non-Asian population,the efficacy of this therapy for Asian population in real-world setting remains poorly detailed.We aimed to determine outcomes and identify predictors of response in hepatocellular carcinoma(HCC)patients treated by Y-90 SIRT.Methods:We retrospectively enrolled 52 HCC patients receiving Y-90 SIRT at our tertiary center between 2014 and 2019.Overall survival(OS),progression free survival(PFS),and predictive factors were determined by Kaplan-Meier method and Cox-proportional hazard analysis.Results:Of the 52 patients(81％male,mean age 64.9 years),71％and 29％were classified as Barcelona Clinic Liver Cancer stage C and B HCC,respectively;63％had portal vein thrombosis,and 35％had objective tumor response defined by the modified Response Evaluation Criteria in Solid Tumors(mRE-CIST)criteria.OS and PFS were 11.0 and 2.4 months,respectively.Two patients were successfully down-staged and further underwent surgical resection.Multifocal lesion,alpha-fetoprotein(AFP)≥200 ng/mL,and Eastern Cooperative Oncology Group(ECOG)score≥1 were significantly associated with poor sur-vival,with adjusted hazard ratio(95％confidence interval)of 7.7(2.0-29.8),5.4(2.0-14.7),and 3.1(1.0-9.6),respectively(all in P＜0.05).Conclusions:Y-90 SIRT is an effective treatment for the local tumor control of HCC without serious adverse events.Single lesion,AFP level and ECOG status were predictors of response.